194 related articles for article (PubMed ID: 20171036)
41. A randomized comparison of sirolimus-eluting versus bare metal stents in the treatment of diabetic patients with native coronary artery lesions: the DECODE study.
Chan C; Zambahari R; Kaul U; Lau CP; Whitworth H; Cohen S; Buchbinder M;
Catheter Cardiovasc Interv; 2008 Nov; 72(5):591-600. PubMed ID: 18949772
[TBL] [Abstract][Full Text] [Related]
42. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study).
Rahel BM; Laarman GJ; Kelder JC; Ten Berg JM; Suttorp MJ
Am Heart J; 2009 Jan; 157(1):149-55. PubMed ID: 19081412
[TBL] [Abstract][Full Text] [Related]
43. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
[TBL] [Abstract][Full Text] [Related]
44. Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions.
Serruys PW; Ong AT; Morice MC; De Bruyne B; Colombo A; Macaya C; Richardt G; Fajadet J; Hamm C; Dawkins K; O'Malley AJ; Bressers M; Donohoe D
EuroIntervention; 2005 Aug; 1(2):147-56. PubMed ID: 19758896
[TBL] [Abstract][Full Text] [Related]
45. Five-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.
Shen ZJ; García-García HM; Garg S; Onuma Y; Schenkeveld L; van Domburg RT; Serruys PW;
Catheter Cardiovasc Interv; 2009 Dec; 74(7):979-86. PubMed ID: 19753636
[TBL] [Abstract][Full Text] [Related]
46. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study.
van der Hoeven BL; Liem SS; Jukema JW; Suraphakdee N; Putter H; Dijkstra J; Atsma DE; Bootsma M; Zeppenfeld K; Oemrawsingh PV; van der Wall EE; Schalij MJ
J Am Coll Cardiol; 2008 Feb; 51(6):618-26. PubMed ID: 18261680
[TBL] [Abstract][Full Text] [Related]
47. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
[TBL] [Abstract][Full Text] [Related]
48. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
[TBL] [Abstract][Full Text] [Related]
49. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the CENTURY II randomized clinical trial.
Iñiguez A; Chevalier B; Richardt G; Neylon A; Jiménez VA; Kornowski R; Carrie D; Moreno R; Barbato E; Serra-Peñaranda A; Guiducci V; Valdés-Chávarri M; Yajima J; Wijns W; Saito S;
Catheter Cardiovasc Interv; 2020 Feb; 95(2):175-184. PubMed ID: 31033154
[TBL] [Abstract][Full Text] [Related]
50. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
51. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study).
Atary JZ; van der Hoeven BL; Liem SS; Jukema JW; van der Bom JG; Atsma DE; Bootsma M; Zeppenfeld K; van der Wall EE; Schalij MJ
Am J Cardiol; 2010 Jul; 106(1):4-12. PubMed ID: 20609639
[TBL] [Abstract][Full Text] [Related]
52. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ; Sudhir K; Hermiller JB; Gordon PC; Ferguson J; Yaqub M; Sood P; Su X; Yakubov S; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2010 Dec; 3(12):1229-39. PubMed ID: 21232716
[TBL] [Abstract][Full Text] [Related]
53. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
[TBL] [Abstract][Full Text] [Related]
54. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
Kimura T; Morimoto T; Natsuaki M; Shiomi H; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Takatsu Y; Nishikawa H; Yamamoto Y; Nakagawa Y; Hayashi Y; Iwabuchi M; Umeda H; Kawai K; Okada H; Kimura K; Simonton CA; Kozuma K;
Circulation; 2012 Sep; 126(10):1225-36. PubMed ID: 22824435
[TBL] [Abstract][Full Text] [Related]
55. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
[TBL] [Abstract][Full Text] [Related]
56. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
57. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
[TBL] [Abstract][Full Text] [Related]
58. Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients.
Yachi S; Tanabe K; Tanimoto S; Aoki J; Nakazawa G; Yamamoto H; Otsuki S; Yagishita A; Kishi S; Nakano M; Taniwaki M; Sasaki S; Nakajima H; Mise N; Sugimoto T; Hara K
Am J Kidney Dis; 2009 Aug; 54(2):299-306. PubMed ID: 19394736
[TBL] [Abstract][Full Text] [Related]
59. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
60. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial.
Serruys PW; Ong AT; van Herwerden LA; Sousa JE; Jatene A; Bonnier JJ; Schönberger JP; Buller N; Bonser R; Disco C; Backx B; Hugenholtz PG; Firth BG; Unger F
J Am Coll Cardiol; 2005 Aug; 46(4):575-81. PubMed ID: 16098418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
